Inhibition of placental growth factor activity reduces the severity of fibrosis, inflammation, and portal hypertension in cirrhotic mice

Hepatology

Volumn 53, Issue 5, 2011, Pages 1629-1640

  Steenkiste, Christophe Van ^a   Ribera, Jordi ^b   Geerts, Anja ^a   Pauta, Montse ^b   Tugues, Sònia ^b,c   Casteleyn, Christophe ^d   Libbrecht, Louis ^a   Olievier, Kim ^a   Schroyen, Ben ^e   Reynaert, Hendrik ^e   van Grunsven, Leo A ^e   Blomme, Bram ^a   Coulon, Stephanie ^a   Heindryckx, Femke ^a   De Vos, Martine ^a   Stassen, Jean Marie ^f   Vinckier, Stefan ^g   Altamirano, Jose ^b   Bataller, Ramón ^b   Carmeliet, Peter ^g,h   Van Vlierberghe, Hans ^a   Colle, Isabelle ^a   Morales Ruiz, Manuel ^b   more..

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b UNIVERSITY OF BARCELONA   (Spain)

^c UPPSALA UNIVERSITY   (Sweden)

^d GHENT UNIVERSITY   (Belgium)

^e VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^f ThromboGenics NV   (Belgium)

^g DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^h UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI VASCULOTROPIN RECEPTOR 1 ANTIBODY; CARBON TETRACHLORIDE; IMMUNOLOGIC AGENT; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PLACENTAL GROWTH FACTOR; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY BLOOD FLOW; ARTICLE; CELL PROLIFERATION; CHEMOTAXIS; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME PHOSPHORYLATION; GENE LOSS; HEART RATE; HEPATITIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOTHERAPY; LIVER FIBROSIS; MALE; MEAN ARTERIAL PRESSURE; MESENTERIC ARTERY; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PORTAL HYPERTENSION; PORTAL VEIN BLOOD PRESSURE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; SPLEEN WEIGHT; STELLATE CELL; UPREGULATION; WILD TYPE;

ANIMALS; HEPATITIS; HUMANS; HYPERTENSION, PORTAL; LIVER CIRRHOSIS; MALE; MICE; PREGNANCY PROTEINS; RATS; RATS, WISTAR; SEVERITY OF ILLNESS INDEX;

EID: 79955081875     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.24238     Document Type: Article

References (23)

1. Fernandez M, Semela D, Bruix J, Colle I, Pinzani M, Bosch J. Angiogenesis in liver disease. J Hepatol 2009; 50: 604-620.
2. Thabut D, Shah V. Intrahepatic angiogenesis and sinusoidal remodeling in chronic liver disease: new targets for the treatment of portal hypertension? J Hepatol 2010; 53: 976-980.
3. Taura K, De Minicis S, Seki E, Hatano E, Iwaisako K, Osterreicher CH, et al. Hepatic stellate cells secrete angiopoietin 1 that induces angiogenesis in liver fibrosis. Gastroenterology 2008; 135: 1729-1738.
4. Wang YQ, Ikeda K, Ikebe T, Hirakawa K, Sowa M, Nakatani K, et al. Inhibition of hepatic stellate cell proliferation and activation by the semisynthetic analogue of fumagillin TNP-470 in rats. Hepatology 2000; 32: 980-989.
5. Semela D, Das A, Langer D, Kang N, Leof E, Shah V. Platelet-derived growth factor signaling through ephrin-b2 regulates hepatic vascular structure and function. Gastroenterology 2008; 135: 671-679.
6. Mejias M, Garcia-Pras E, Tiani C, Miquel R, Bosch J, Fernandez M. Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats. Hepatology 2009; 49: 1245-1256.
7. Tugues S, Fernandez-Varo G, Munoz-Luque J, Ros J, Arroyo V, Rodes J, et al. Antiangiogenic treatment with sunitinib ameliorates inflammatory infiltrate, fibrosis, and portal pressure in cirrhotic rats. Hepatology 2007; 46: 1919-1926.
8. Patsenker E, Popov Y, Stickel F, Schneider V, Ledermann M, Sagesser H, et al. Pharmacological inhibition of integrin alphavbeta3 aggravates experimental liver fibrosis and suppresses hepatic angiogenesis. Hepatology 2009; 50: 1501-1511.
9. Fischer C, Jonckx B, Mazzone M, Zacchigna S, Loges S, Pattarini L, et al. Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell 2007; 131: 463-475.
10. Van de Veire S, Stalmans I, Heindryckx F, Oura H, Tijeras-Raballand A, Schmidt T, et al. Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease. Cell 2010; 141: 178-190.
11. DiPalma T, Tucci M, Russo G, Maglione D, Lago CT, Romano A, et al. The placenta growth factor gene of the mouse. Mamm Genome 1996; 7: 6-12.
12. Autiero M, Luttun A, Tjwa M, Carmeliet P. Placental growth factor and its receptor, vascular endothelial growth factor receptor-1: novel targets for stimulation of ischemic tissue revascularization and inhibition of angiogenic and inflammatory disorders. J Thromb Haemost 2003; 1: 1356-1370.
13. Van Steenkiste C, Geerts A, Vanheule E, Van Vlierberghe H, De Vos F, Olievier K, et al. Role of placental growth factor in mesenteric neoangiogenesis in a mouse model of portal hypertension. Gastroenterology 2009; 137: 2112-2124.
14. Lassen U, Nielsen D, Sorensen M, Ronnengart E, Eldrup K, Bentzon K, et al. A phase I, dose escalation study of TB-403, a monoclonal antibody directed against PlGF, in patients with solid tumors [Abstract]. Mol Cancer Ther 2009; 8: A111.
15. Riisbro R, Larsson L, Winsted L, Niskanen T, Pakola S, Stassen JM, et al. A first-in-man phase I dose escalation study of TB403, a monoclonal antibody directed against PlGF in healthy male subjects [Abstract]. Mol Cancer Ther 2009; 8: A3.
16. Eliceiri BP, Klemke R, Stromblad S, Cheresh DA. Integrin alphavbeta3 requirement for sustained mitogen-activated protein kinase activity during angiogenesis. J Cell Biol 1998; 140: 1255-1263.
17. Khurana R, Moons L, Shafi S, Luttun A, Collen D, Martin JF, et al. Placental growth factor promotes atherosclerotic intimal thickening and macrophage accumulation. Circulation 2005; 111: 2828-2836.
18. Huang XX, McCaughan GW, Shackel NA, Gorrell MD. Up-regulation of proproliferative genes and the ligand/receptor pair placental growth factor and vascular endothelial growth factor receptor 1 in hepatitis C cirrhosis. Liver Int 2007; 27: 960-968.
19. Salcedo Mora X, Sanz-Cameno P, Medina J, Martin-Vilchez S, Garcia-Buey L, Borque MJ, et al. Association between angiogenesis soluble factors and disease progression markers in chronic hepatitis C patients. Rev Esp Enferm Dig 2005; 97: 699-706.
20. Van Steenkiste C, Trachet B, Casteleyn D, van Loo L, Van Hoorebeke L, Segers P, et al. Vascular corrosion casting: analyzing wall shear stress in the portal vein and vascular abnormalities in portal hypertensive and cirrhotic rodents. Lab Invest 2010; 90: 1558-1572.
21. Aleffi S, Petrai I, Bertolani C, Parola M, Colombatto S, Novo E, et al. Upregulation of proinflammatory and proangiogenic cytokines by leptin in human hepatic stellate cells. Hepatology 2005; 42: 1339-1348.
22. Autiero M, Waltenberger J, Communi D, Kranz A, Moons L, Lambrechts D, et al. Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1. Nat Med 2003; 9: 936-943.
23. Usui R, Shibuya M, Ishibashi S, Maru Y. Ligand-independent activation of vascular endothelial growth factor receptor 1 by low-density lipoprotein. EMBO Rep 2007; 8: 1155-1161.